J&J, Bayer Ask To Strike Doc's Testimony In Xarelto Trial
Law360, New York (August 14, 2017, 6:07 PM EDT) -- Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. on Monday asked the Louisiana federal judge overseeing the third bellwether trial over the blood thinner Xarelto to strike testimony from a physician about a proposed label change redlined by the U.S. Food and Drug Administration.
Before Dora Mingo’s trial kicked off on Aug. 7, her regulatory experts — including Dr. Suzanne Parisian, a physician and former FDA medical officer — conceded that it was the FDA that struck proposed language about a blood clotting test called Neoplastin PT from Xarelto’s label before the blood thinner was approved, the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.